- Home
- ETJ vs ANAB Comparison
ETJ vs ANAB Comparison
Compare ETJ & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETJ
- ANAB
- Stock Information
- Founded
- ETJ 2007
- ANAB 2005
- Country
- ETJ United States
- ANAB United States
- Employees
- ETJ N/A
- ANAB N/A
- Industry
- ETJ Finance Companies
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- ETJ Finance
- ANAB Health Care
- Exchange
- ETJ Nasdaq
- ANAB Nasdaq
- Market Cap
- ETJ 578.8M
- ANAB 621.1M
- IPO Year
- ETJ N/A
- ANAB 2017
- Fundamental
- Price
- ETJ $8.98
- ANAB $26.55
- Analyst Decision
- ETJ
- ANAB Buy
- Analyst Count
- ETJ 0
- ANAB 10
- Target Price
- ETJ N/A
- ANAB $44.25
- AVG Volume (30 Days)
- ETJ 175.6K
- ANAB 515.5K
- Earning Date
- ETJ 01-01-0001
- ANAB 08-04-2025
- Dividend Yield
- ETJ 8.30%
- ANAB N/A
- EPS Growth
- ETJ N/A
- ANAB N/A
- EPS
- ETJ N/A
- ANAB N/A
- Revenue
- ETJ N/A
- ANAB $111,872,000.00
- Revenue This Year
- ETJ N/A
- ANAB N/A
- Revenue Next Year
- ETJ N/A
- ANAB $24.39
- P/E Ratio
- ETJ N/A
- ANAB N/A
- Revenue Growth
- ETJ N/A
- ANAB 387.20
- 52 Week Low
- ETJ $7.20
- ANAB $12.21
- 52 Week High
- ETJ $8.47
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- ETJ 56.41
- ANAB 70.24
- Support Level
- ETJ $8.60
- ANAB $23.10
- Resistance Level
- ETJ $9.09
- ANAB $26.17
- Average True Range (ATR)
- ETJ 0.08
- ANAB 1.33
- MACD
- ETJ 0.00
- ANAB 0.27
- Stochastic Oscillator
- ETJ 77.31
- ANAB 100.00
About ETJ Eaton Vance Risk-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Risk-Managed Diversified Equity Income Fund is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income and gains, with a secondary objective of capital appreciation. The group invests in various sectors such as financials, healthcare, consumer discretionary, consumer staples, industrials, energy, utilities, telecommunication services, and materials. Under normal market conditions, the Fund's investment program consists of majorly owning a diversified portfolio of common stocks and employing a variety of options strategies.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).